Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Oncology | History Defined

Avammune’s big bet: Why the future of cancer treatment may come in a pill

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherapies designed for broader patient access.

The Economic Times

Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest

Three studies add to evidence that jabs could be part of cancer-fighting toolkit to cut risk of developing or dying from disease

The Guardian - UK

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its lar

MarketBeat

Doctors hail cancer injection that can destroy entire tumors

The results of the trial will be presented during the American Society of Clinical Oncology annual meeting in Chicago

The Independent UK

Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim

Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses

The Guardian - UK

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

FLORENCE, Italy and NEW YORK, May 29, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present safety and preliminary efficacy for the…

AAP

Read news from The Economist, FT, and more,
with one subscription

Want to Stay Current on Latest in Cancer Prevention and Treatment? Free Service from NCCN Can Help

PLYMOUTH MEETING, Pa., May 27, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—the nonprofit alliance of leading cancer centers responsible for essential NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that providers rely on worldwide—has launched a new, free service. Anyone is now able to sign up for weekly…

AAP

MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates

MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seni

MarketBeat

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several ear

MarketBeat

Manish Singh's View of Oncology Innovation Through Clinical Insight and Long-Term Thinking

Dr. Singh's professional journey spans scientific research, venture investing, and biotechnology leadership, experiences that collectively shaped his perspective on how meaningful innovation occurs.

International Business Times

DOSIsoft Launches DOSIsoft Theranostics, a Dedicated Entity to Accelerate Software Innovation for Personalized Nuclear Medicine and Theranostics

PARIS, May 26, 2026 /PRNewswire/ -- Ahead of SNMMI 2026, DOSIsoft, a leading provider of dosimetry software for radiation oncology and nuclear medicine, today announced the launch of DOSIsoft Theranostics, a dedicated entity focused on developing theranostics software for broader routine clinical adoption. As an independent player fully dedicated to…

AAP

Philadelphia Nurse spots her Jamaican Co-Worker’s Name on her Hospital’s Memorial Paper for Patients Who Passed Away. Then She walked in Alive

Jamaican nurse misunderstood her Philadelphia hospital’s memorial paper for late patients and wrote her own name with “Thin Mints.”

The Mary Sue

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline. Speaking at a Stifel-hosted event, H

AAP

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

FLORENCE, Italy and NEW YORK, May 25, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and…

International Business Times

Could Launching Tumors Into Space Help Medicine Beat Cancer?

A new experiment is seeking to validate whether living cancer samples can be prepared, operated, monitored, and recovered under flight conditions without crew intervention in their standardized format for pharma-grade preclinical research.

MarketBeat

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

MarketBeat

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer. On an

AAP

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.

MarketBeat

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones. The discussio

MarketBeat

Auna Q1 Earnings Call Highlights

Auna (NYSE:AUNA) reported stronger first-quarter revenue and cash flow across its regional healthcare platform, while adjusted EBITDA declined as the company absorbed revenue adjustments in Peru and higher payroll costs in Mexico and Colombia. Executive Chairman and President Jesús Zamora said the

AAP

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for the treatment of pancreatic cancer. The study,…

MarketBeat

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladde

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.